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Purpose: To characterize the molecular mechanism underpinning early-onset macular drusen (EOMD), a
phenotypically severe subtype of age-related macular degeneration (AMD), in a subgroup of patients.
Design: Multicenter case series, in vitro experimentation, and retrospective analysis of previously reported
variants.
Participants: Seven families with apparently autosomal dominant EOMD.
Methods: Patients underwent a comprehensive ophthalmic assessment. Affected individuals from families A,
B, and E underwent whole exome sequencing. The probands from families C, D, F, and G underwent Sanger
sequencing analysis of the complement factor H (CFH) gene. Mutant recombinant factor H like-1 (FHL-1) proteins
were expressed in HEK293 cells to assess the impact on FHL-1 expression and function. Previously reported
EOMD-causing variants in CFH were reviewed.
Main Outcome Measures: Detailed clinical phenotypes, genomic ﬁndings, in vitro characterization of mu-
tation effect on protein function, and postulation of the pathomechanism underpinning EOMD.
Results: All affected participants demonstrated bilateral drusen. The earliest reported age of onset was 16
years (median, 46 years). Ultra-rare (minor allele frequency [MAF], 0.0001) CFH variants were identiﬁed as the
cause of disease in each family: CFH c.1243del, p.(Ala415ProfsTer39) het; c.350þ1G/T het; c.619þ1G/A het,
c.380G/A, p.(Arg127His) het; c.694C/T p.(Arg232Ter) het (identiﬁed in 2 unrelated families in this cohort); and
c.1291T/A, p.(Cys431Ser). All mutations affect complement control protein domains 2 through 7, and thus are
predicted to impact both FHL-1, the predominant isoform in Bruch’s membrane (BrM) of the macula, and factor H
(FH). In vitro analysis of recombinant proteins FHL-1R127H, FHL-1A415f/s, and FHL-1C431S demonstrated that they
are not secreted, and thus are loss-of-function proteins. Review of 29 previously reported EOMD-causing mu-
tations found that 75.8% (22/29) impact FHL-1 and FH. In total, 86.2% (25/29) of EOMD-associated variants
cause haploinsufﬁciency of FH or FHL-1.
Conclusions: Early-onset macular drusen is an underrecognized, phenotypically severe subtype of AMD. We
propose that haploinsufﬁciency of FHL-1, the main regulator of the complement pathway in BrM, where drusen
develop, is an important mechanism underpinning the development of EOMD in a number of cases. Under-
standing the molecular basis of EOMD will shed light on AMD pathogenesis given their pathologic
similarities. Ophthalmology 2019;126:1410-1421 ª 2019 by the American Academy of Ophthalmology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.
See Commentary on page 1422.Age-related macular degeneration (AMD) represents a
leading cause of irreversible vision loss, accounting for
8.7% of global blindness.1 The condition is characterized by
inﬂammation and the deposition of extracellular material, in
the form of drusen, in Bruch’s membrane (BrM). Drusen
can cause metabolic disruption that leads to dysfunction1410 ª 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativec
org/licenses/by/4.0/). Published by Elsevier Inc.and death of retinal pigment epithelium. Later stages of
AMD may be characterized by geographic atrophy or
choroidal neovascularization; these are associated with
severe loss of central vision. It is now widely accepted
that an excessive inﬂammatory response driven by
inadequate regulation of the complement cascade is aommons.
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degeneration is a disease of multifactorial cause with a
strong genetic component, and the role of the complement
pathway in AMD pathogenesis is corroborated by the
implication of genetic variants in a number of complement
factors with AMD risk.3,4 Genetic variants associated with
AMD represent a broad allelic range, from common poly-
morphisms (minor allele frequency [MAF], >1%) that
confer a relatively low risk of disease5e9 to relatively rare
variants (MAF, <1%) that demonstrate high penetrance, for
example, the p.(Arg1210Cys) substitution in complement
factor H (CFH).10
The complement system is a crucial component of host
innate immunity.11 It is a cascade system comprising 3
activation pathwaysdclassical, lectin, and alternatived
each of which is engaged uniquely, but that converge on 3
common goals: modifying the membrane of an unwanted
cell for phagocyte recognition, generation of membrane
attack complexes for cell lysis, and promoting an
inﬂammatory response.2 Complement can activate on all
surfaces, both host or foreign, so the host requires
mechanisms to prevent inappropriate self-directed dam-
age.12 The alternative pathway (AP) is constantly active at a
low level and contains a positive feedback loop to allow
rapid ampliﬁcation of the complement response. Tight
regulation is required to maintain balanced immune
homeostasis, and it is increasingly recognized that
defective regulation of the AP plays a central role in
human disease.13,14
The CFH gene encodes a 155-kDa plasma protein known
as factor H (FH)15 that functions as a complement regulator
by binding to host surfaces to protect them against
complement activation. It mainly exerts its effect on the
AP, negatively regulating the positive feedback loop.
Factor H harbors 20 complement control protein (CCP)
domains, each comprising 60 amino acids, that can be
grouped into 3 functional domains: CCP domains 1
through 4 form a binding site for cofactor activity,
whereas both CCP domains 6 through 8 and CCP
domains 19 and 20 facilitate binding of FH via
glycosaminoglycans to cell surfaces and extracellular
matrices (ECMs).2,16
Disease-causing variants in CFH result in 3 distinct
pathologic syndromes: atypical hemolytic uremic syndrome,
C3 glomerulopathy (a clinical entity that encompasses C3
glomerulonephritis and dense deposit disease, formerly
membranoproliferative glomerulonephronophthitis type II),
and AMD. An apparent genotypeephenotype correlation
exists whereby most atypical hemolytic uremic
syndromeecausing variants affect CCP domains 19 and
20,17 whereas variants associated with AMD predominantly
affect CCPs 1 through 4 and 6 through 8.18,19 Boon et al20 in
2008 and van de Ven et al21 in 2012 showed that an early-
onset subtype of AMD was caused by monogenic inheri-
tance of ultrarare variants in CFH. This AMD subtype
(which for clarity we term early-onset macular drusen
[EOMD]) demonstrates a much earlier age of onset (mean
age, 50 years), causing many more years of substantial
visual loss than AMD.20,21 Few EOMD cases have been
reported since.22e25Alternative splicing of CFH exon 9 produces a variant of
FH known as factor H like 1 (FHL-1) that is identical to
CCPs 1 through 7 of FH, has a unique carboxy-terminal tail
of 4 amino acids, and is signiﬁcantly smaller (49 kDa).
Recent work has suggested that FHL-1 retains the same
regulatory functions as FH and is able to bind to surfaces via
its single glycosaminoglycan-interaction domain at CCP
domains 6 and 7 to regulate the complement cascade.26
Impaired FH and FHL-1 function leads to disease as a
result of inﬂammation and cellular debris mishandling
because of excessive AP activation driven by defective
regulation of the complement cascade.2,26 Genetic studies of
AMD fail to distinguish between FH and FHL-1. Factor H-
like 1 is the major isoform present within BrM of the
retina,26,27 a major site of AMD pathogenesis and where
drusen, the characteristic lesions of AMD, form. It has been
suggested that it is this isoform that protects BrM against
complement activation.26 In this study, we performed
functional and variant localization analysis of the EOMD-
causing variants that lie within FHL-1 and deﬁned the
mechanism responsible for a subgroup of patients affected
by this phenotypically severe condition.
Methods
Ethics and Patient Recruitment
Ethics committee approval was obtained from the North West
Regional Ethics Committee for all aspects of this study (identiﬁer,
15/YH/0365), and the protocol observed the tenets of the Decla-
ration of Helsinki. Written informed consent was obtained from
each study participant as an essential prerequisite for study inclu-
sion. Patients with EOMD were included in our analysis. Given the
heterogeneous nature of drusen and to limit bias, we did not select
patients based on the type or size of drusen they demonstrated.
Clinical Assessment
Each patient underwent full ophthalmic assessment including vi-
sual acuity and dilated fundus examination. Fundus photographs
were obtained using Ultra-Wideﬁeld Optos color fundus imaging
(Optos plc, Dunfermlin, UK). Fundus autoﬂuorescence imaging
was conducted using either the Spectralis (Heidelberg Engineering
Ltd, Heidelberg, Germany) or ultra-wideﬁeld confocal scanning
laser imaging (Optos plc). OCT was performed using the Spectralis
OCT platform (Heidelberg Engineering). Electroretinography was
performed to standards speciﬁed by the International Society for
Clinical Electrophysiology of Vision. Clinical history also was
obtained to discern the presence of additional health problems.
Whole-Exome Sequencing
Whole-exome sequencing, performed as outlined in a previous
publication,28 was carried out as part of an ongoing study on
inherited retinal disease (United Kingdom Inherited Retinal
Dystrophy Consortium) in families without a molecular diagnosis
after next generation sequencing (NGS) screening for a panel of
105 or 176 genes known to cause inherited retinal dystrophy.
Detailed methodology can be found in Supplemental Data A
(available at www.aaojournal.org). Whole-exome sequencing
data from affected relatives (A:II.1 and A:II.3; E:III.11 and E:II.8)
was analyzed for shared rare variants. Variants in genes known to
be involved in inherited retinal disease were examined as a priority.
Identiﬁed variants were interpreted according to the Association for1411
Ophthalmology Volume 126, Number 10, October 2019Clinical Genetic Science Best Practice Guidelines for Variant
Classiﬁcation 2018.
Sanger Sequencing of CFH
Seventy-ﬁve patients diagnosed with dominant or early drusen
whose results were negative for the EFEMP1 c.1033C/T;
p.(Arg345Trp) variant were identiﬁed retrospectively from a re-
ferrals database and were subjected to screening for variants in the
CFH gene by Sanger sequencing. The coding exons and ﬂanking
intronic sequences of CFH (NM_000186) plus an additional 4
amino acids unique to the alternative transcript FHL-1 (exon 10,
NM_0010149975) were ampliﬁed by polymerase chain reaction
and subject to bidirectional Sanger sequencing (see Supplemental
Data A for details). Variants were interpreted as before (see
“Whole-Exome Sequencing”).
Functional Characterization of Genetic Variants
N-terminal His-tagged DNA sequences encoding human FHL-1 or
mutant versions of FHL-1 were synthesized and sub-cloned in to
pcDNA3.1 by GeneArt (Invitrogen; Carlsbad, CA). Plasmid DNA
was transfected into HEK293 cells using polyethylenimine, and
culture media was harvested from transfected cells at 24, 48, 72,
and 144 hours. His-tagged recombinant proteins were puriﬁed from
the harvested media using Amintra Ni-NTA afﬁnity resin (Expe-
deon, Cambridge, UK) by gravity ﬂow chromatography. Cell ly-
sates were made from transfected HEK293 cells and quantiﬁed
using the Pierce BCA assay (Thermoﬁsher Scientiﬁc, Waltham,
MA). Western blotting was conducted as previously described.26
Detailed methodologies for plasmid preparation, transformation
and transfection, puriﬁcation of recombinant proteins, and
Western blotting can be found in Supplemental Data A.
Results
Retinal Findings
We report 10 individuals from 7 unrelated families with a mono-
genic form of EOMD (Fig S1, available at www.aaojournal.org).
Retinal phenotypes are summarized below and in Table 1.
Detailed ophthalmic histories for each participant can be found
in Supplemental Data B (available at www.aaojournal.org). None
of the individuals included in this study showed evidence of
renal disease. The median age of drusen onset was 46 years. The
average age at onset in our cohort is skewed by late
identiﬁcation of disease in individual B:II.2, who did not receive
a diagnosis until 80 years of age. The earliest documented age at
which drusen were identiﬁed was 16 years in individual A:II.1,
younger than has been reported previously in EOMD. In all
affected study participants, drusen were bilateral and broadly
symmetrical and were visible on fundus examination or color
photographs (Fig S2, available at www.aaojournal.org), fundus
autoﬂuorescence images (Fig 3), OCT images (Fig S4, available
at www.aaojournal.org), or a combination thereof. The impact on
visual acuity was varied, from no apparent impact (B:I.1) to mild
(A:II.3, A:II.1, C:I.2, D:I.7, E:III.11, F:II.2, and G:III.7), moderate
(D:II:2 and E:II.2), and severe (B:II.2) visual loss. As shown in
Figures S2 through S4, varying phenotypes and degrees of disease
severity were present in study participants. This possibly reﬂects
that individuals in our cohort represent a range of ages and thus
various disease stages. However, in younger participants, we
cannot rule out nonprogressive disease at this time.
In family A, both affected siblings demonstrated small drusen,
scattered throughout the retina in an appearance typical of basal
laminar drusen (i.e., so-called stars-in-the-sky appearance).1412Ophthalmic examination of their mother found that she was un-
affected. Proband B:I.1 from family B was found to have multiple
small drusen at the macula and nasal to the optic discs. His mother,
B:II.2, was more advanced, showing drusen as well as atrophy at
both the macula and the nasal retina. Participant C:I.1 demon-
strated central scotomata and drusen surrounding a region of cen-
tral atrophy that extended to the vascular arcades. She showed
patchy atrophy with reticular and drusenoid features in the retinal
periphery with midperipheral sparing. Her mother and sister also
had received a diagnosis of macular drusen. The proband from
family D (D:I.7) demonstrated multiple large drusen bilaterally
associated with atrophy of the right macula. Her affected father
(D:II.2) demonstrated advanced neovascular macular degeneration.
Family history revealed the proband’s paternal aunt (D:II.1) and
great grandfather (D.IV.6) had experienced visual deterioration in
their forties. It was also noted that her paternal great aunt (D.IV.2)
and great uncle (D:IV.5) were affected in their ﬁfties, although no
further information was available. Her paternal grandmother
(D:III.3) died at 56 years of age, and it is not known whether she
also was affected. The proband from family E (E:III.11) demon-
strated central vision problems. Fundus autoﬂuorescence revealed
hypoautoﬂuorescence centrally resulting from geographic atrophy
with a surrounding ring of hyperautoﬂuorescence and drusen nasal
to the optic disc. Pigmentary changes and drusen also were seen in
the peripheral retina. Her affected son (E:II.8) was found to have
small, sparse macular drusen at 40 years of age. Family history
revealed multiple affected members in family E. Funduscopy of the
proband from family F (F:II.2) revealed isolated sparse drusen
within the temporal macula. At the time of her diagnosis, her
mother (F:III.2) was being treated for choroidal neovascularization.
Proband G:III.7 from family G demonstrated clustered drusen
spread throughout the macula, with early nonfoveal geographic
atrophy in the left eye. Her sister (G:III.3) and 2 brothers (G:III.1
and G.III.4) also were affected. Her mother died at 30 years of age
and her father died at 80 years of age with no known visual
problems.
Genetic Findings
The probands from families A, B, and E underwent testing for
variants in the coding and ﬂanking intronic regions of 105 or 176
known retinal dystrophy-causing genes, including a number of
genes associated with macular drusen (ABCA4, NM_000350; CA4,
NM_000717; CNGB3, NM_019098; EFEMP1, NM_001039348;
PROM1, NM_006017; and TIMP3, NM_000362). No putative
disease-causing or carrier variants were identiﬁed. Subsequently,
each was recruited to the United Kingdom Inherited Retinal Dys-
trophy Consortium study, and whole-exome sequencing was con-
ducted on DNA from the affected sibling pair of family A (A:II.1
and A:II.3), the proband of family B (B:II.2), and the affected
mother (E.II.2) and son (E.I.1) of family E. In each family, an
ultrarare (MAF, <0.0001) or novel heterozygous CFH variant was
identiﬁed as the probable cause of disease (Table 1). NGS analysis
and interpretation of variants can be found in Supplemental Data C
(available at www.aaojournal.org).
A cohort of 75 patients diagnosed with macular drusen and
demonstrating negative results for the EFEMP1 c.1033C/T
p.(Arg345Trp) variant were screened for variants in the coding
and ﬂanking intron regions of the CFH gene (NM_000186),
including an alternatively encoded exon from the transcript
NM_0010149975. Four patients (the probands of families C, D, F,
and G: C:I.2, D:I.7, F:II.2, and G:III.7) were found to harbor novel
or ultrarare (MAF, <0.0001) heterozygous variants in the CFH
gene (Table 1).
In total, 6 different CFH variants were identiﬁed in 7 EOMD
families (Table 1). Segregation analysis was performed where
Table 1. Phenotypic and Genetic Findings in Early-Onset Macular Drusen Patients with CFH Mutations
Study
Identiﬁcation* Gender
Age (yrs)
Family
Historyy Phenotype
Snellen Visual
Acuity (logMAR)
Electrophysiology
Findings Mutation
Complement
Control
Protein
Domain
GnomAD
Allele Count
(Allele
Frequency)
Age at
onset*
At Most
Recent
Examination Right Eye Left Eye
A:II.3 M 18 51 Yes Bilateral, scattered
or widespread
early-onset
drusen, RPE
mottling at the
fovea, reduced
VA.
þ5.75
(0.22; 6/9e1)
þ3.75
(0.0; 6/6)
Normal and
grossly
symmetrical
light-adapted
response.
Slightly reduced
dark-adapted
response in
right eye
suggesting
asymmetrical
rod
involvement.
Normal EOG
results.
c.1243del,
p.(Ala415Profs*39)
het
7 d
A:II.1 M 16 49 Bilateral
widespread
drusen,
concentrated
temporal to and
within the
macula.
6/3.8e1 6/3.8e1 Normal and
grossly
symmetrical
light-adapted
response.
Slightly reduced
dark-adapted
response in left
eye suggesting
asymmetrical
rod
involvement.
Normal EOG
results.
B:II.2 F 80 89 Yes Bilateral,
symmetrical,
outer retinal
atrophy,
multiple drusen,
severe visual
loss.
d d NA c.350þ1G/T het 2 1/245972
(0.000004066)
B:I.1 M 61 61 Multiple drusen
bilaterally,
pattern similar
to that seen in
affected mother
(B.II.1).
6/6 6/6 NA
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Study
Identiﬁcation* Gender
Age (yrs)
Family
Historyy Phenotype
Snellen Visual
Acuity (logMAR)
Electrophysiology
Findings Mutation
Complement
Control
Protein
Domain
GnomAD
Allele Count
(Allele
Frequency)
Age at
onset*
At Most
Recent
Examination Right Eye Left Eye
C:I.2 F 54 64 Yes Bilateral drusen
surrounding
central atrophy
and extending
into the
arcades. Patchy
atrophy in the
peripheral
retina with
reticular and
drusenoid
features.
6/6 6/15 NA c.694C/T
p.(Arg232Ter) hetz
4 2/244650
(0.000008175)
D:I.7 F 26 50 Yes Large “colloid”
drusen.
6/5 6/5 NA c.694C/T
p.(Arg232Ter) hetz
4 2/244650
(0.000008175)
D:II.2 M 50 64 Bilateral retinal
drusenoid
dystrophy with
CNV and
signiﬁcant
scarring.
1/60 6/24 NA
E:II.2 F 50 52 Yes Early-onset
macula
dystrophy,
macular and
midperipheral
drusen.
6/120 (1.34) 6/96 (1.24) Extinguished
PERGs, normal
EOG results,
normal ERG
results; Ishihara:
1/17 right eye,
2/17 left eye
c.1291T/A,
p.(Cys431Ser) hetz
6 1/245702
(0.000004070)
E:III.2 M 40 53 Bilateral small,
sparse drusen at
the maculae.
6/4 6/7.5 NA
F:II.2 F 46 54 Yes Isolated sparse
drusen within
the macula and
temporal
raphes.
6/6
(e4/e1.00  180)
6/4.8
(e4.50/e1.00  170)
NA c.380G/A,
p.(Arg127His) hetz
2 2/121206
(0.0000165)
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Taylor et al  CFH Mutations Causing Macular Drusenpossible, and the respective variant was segregated with disease
in each case (family members tested, their disease status, and
their genetic status are indicated in Fig S1). Three mutations that
have not been reported previously in association with disease
represent novel EOMD-causing mutations: CFH c.1243del,
p.(Ala415ProfsTer39) het; CFH c.350þ1G/T het; and CFH
c.619þ1G/A het. The 3 remaining variants have been reported
previously as disease causing: CFH c.380G/A,
p.(Arg127His)25,29; CFH c.694C/T, p.(Arg232Ter)30 identiﬁed in
2 unrelated families in this cohort; and CFH c.1291T/A,
p.(Cys431Ser), which has been identiﬁed in the homozygous state
underlying membranoproliferative glomerulonephronophthitis type
I31 and dense deposit disease.30 All 6 mutations identiﬁed in this
study affect CCP domains 2 through 7 (Table 1) and therefore are
predicted to impact both FH and FHL-1 (Fig 5).
Functional Characterization of CFH Mutations in
Recombinant Factor H-like 1
Previous studies have shown that rare CFH variants underlying
atypical hemolytic uremic syndrome and EOMD can prevent or
delay secretion of FH32e35 or can impair protein function
severely, causing reduced FH activity22,25,33,36 leading to dysre-
gulation of the complement pathway. However, the impact of rare
CFH variants on the function of the alternative isoform FHL-1
has not been investigated previously. Given the probable impor-
tance of FHL-1 in the EOMD phenotype,26 we investigated the
expression and secretion of mutant forms of FHL-1 containing
the respective mutations identiﬁed in EOMD families A (FHL-
1A415f/s), E (FHL-1C431S), and F (FHL-1R127H) compared with
full-length wild-type FHL-1 (FHL-1402Y). Secreted His-tagged
recombinant protein was puriﬁed from media by afﬁnity chro-
matography, and lysates were made from transfected cells for
analysis of intracellular expression of recombinant wild-type or
mutant FHL-1.
Western blotting for the recombinant proteins revealed that
FHL-1402Y (wild-type) transfected cells secreted a protein
product of expected size (51 kDa, slightly larger than native
FHL-1 because of its N-terminal His-tag modiﬁcation). How-
ever, cells transfected with mutant plasmids did not secrete a
51-kDa protein product at detectable levels within 144 hours of
transfection (Fig 6). Mock (i.e., no vector) transfected cells did
not secrete any detectable protein product, as expected. Next,
we investigated whether the mutant proteins were being
expressed but retained intracellularly by examining lysates
made from the transfected cells. Western blot for intracellular
expression recombinant mutant and wildtype proteins
indicated mutant proteins were not detectable when analyzed
using OX23 (Abcam, Cambridge, UK). In comparison, FHL-
1402Y (wildtype) was present in abundance as indicated by the
intense approximately 51-kDa band despite equal protein
loading as indicated by SOD2 (approximately 26 kDa). These
ﬁndings suggest that although wildtype recombinant FHL-1 is
expressed and secreted, mutant forms of FHL-1 are not. The
absence of mutant proteins intracellularly suggests they are
degraded rapidly by the cell soon after synthesis, possibly
because they are unfolded or unstable, rather than synthesized
and accumulated within the cell because they cannot be
secreted.
Our ﬁndings indicate that the c.1243del, p.(Ala415ProfsTer39)
het; c.1291T/A, p.(Cys431Ser) het; and c.380G/A,
p.(Arg127His) het variants found to underlie disease in families A,
E, and F, respectively, consequently could be considered to
result from loss of function of FHL-1, because the mutant
proteins may be degraded rapidly on synthesis, not secreted by
the cell, or both. Although beyond the scope of this study, it may1415
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of degradation pathways. The remaining putative EOMD-
causing variantsdc.350þ1G/T het (family B), c.694C/T
p.(Arg232Ter) het (families C and D), and c.619þ1G/A het
(family G)dalso are predicted to be loss-of-function variants. This
leads us to suggest that haploinsufﬁciency of FHL-1 is the path-
ologic mechanism underlying this severe, dominant EOMD
phenotype in a subset of patients (i.e., the identiﬁed variants result
in reduction in the amount of functional FHL-1 protein produced,
which is not sufﬁcient to support the normal function of the retinal
pigment epithelium, leading to disease).Review of Previously Reported Early-Onset
Macular Drusen Mutations
Following from this hypothesis, we reviewed previously reported
cases of EOMD to deﬁne further their mutational mechanisms. For
this analysis, we considered literature reports of mutations found to
cause “basal laminar drusen,”20,21 “cuticular drusen,”23,37 and
“early-onset AMD”22,24,25 in the absence of kidney disease. A total
of 25 different variants in 29 families have been reported
(Supplemental Data D, available at www.aaojournal.org). Of these,
19 are nonsynonymous missense variants. Three variantsd
c.1198C/A; p.(Gln400Lys) het, c.2850G/C; p.(Gln950His)
het, and c.3628C/T; p.(Arg1210Cys) hetdeach have been
identiﬁed in 2 unrelated families.23 Six different loss-of-function
(i.e., splice-altering, frameshift, or nonsense) variants also have
been reported. One nonsense variant (c.1222C/T, p.Gln408Ter
het) has been identiﬁed in 2 unrelated families.20 Of the 29 reported
EOMD cases, 75.8% (n ¼ 22) are the result of variants affecting
CCP domains 1 through 7 and impact both FH and FHL-1.
Overall, including the cases reported here, 80.5% (n ¼ 29) of re-
ported EOMD-causing variants (n ¼ 36) affect CCP domains 1
through 7 and thus impact FHL-1 and FH. Furthermore, 100% of
previously reported putative loss-of-function variants (i.e.,
nonsense [n ¼ 2], frameshift [n ¼ 2], and splice-altering [n ¼ 3])
causing EOMD affect CCP domains 1 through 7. Of the 15
missense variants affecting CCP domains 1 through 7, 71.3% (n ¼
11) have evidence that they prevent secretion or severely reduce
protein function. The remaining 4 variants have not been assessed.
In total, 81.8% (n ¼ 18) of previously reported EOMD variants
affecting CCP domains 1 through 7 likely result in hap-
loinsufﬁciency of FHL-1 or FH. Taking into account the variants
reported herein, this ﬁgure increases to 86.2% (n ¼ 25). Thus, there
is considerable evidence in support of the hypothesis that hap-
loinsufﬁciency of FHL-1 is the molecular mechanism underpinning
the development of this severe, early-onset phenotype in a pro-
portion of cases. Two of the other reported missense variants
(p.(Pr0139Ala) and p.(Arg175Gln)) have supporting evidence for
their pathogenicity in that a different amino acid change at the
same position of the peptide has been reported to cause CFH-
related disease with a demonstrated effect on FH serum levels,
suggesting that the mutant protein is not secreted or is degraded on
synthesis or secretion.25,38Figure 3. Fundus autoﬂuorescence imaging in patients with early-onset macu
showing drusen at the macula and extending beyond the vascular arcades. C, D
region (C). E, F, Patient B:II.2, 89 years of age, showing drusen and retinal atroph
years of age, with bilateral macular drusen and drusen nasal to the optic discs. I
atrophy; drusen are present around the atrophy and optic nerve. K, L, Patient D:
drusen. M, N, Patient E:II.2, 53 years of age, showing hypoautoﬂuorescence
hyperautoﬂuorescence and drusen nasal to the optic disc. O, P, Patient F:II.2, 54
of age, showing scattered macular drusen and patches of geographic atrophy.Discussion
This study identiﬁed unrelated families with a history of
EOMD associated with deleterious ultrarare (MAF,
0.0001) heterozygous CFH pathogenic variants. It pro-
vided evidence that clinical signs begin signiﬁcantly earlier
than seen in typical AMD cases; the earliest reported onset
of retinal changes in our cohort is 16 years of age. The 6
different variants identiﬁed (Table 1) all localized within
CCP domains 2 through 7 and consequently impact
FHL-1 and FH. Factor H-like 1 is a short form of FH that
retains all of the regulatory functions of the full-length
protein that has been suggested to be the predominant
regulator of complement in BrM, the ECM layer that lies
beneath the human retina, and the intercapillary septa.26 We
propose that lost or reduced function of FHL-1 leads to
dysregulation of complement turnover in the ECM of BrM
and choriocapillaris and may be the mechanism driving
development of EOMD in these cases; complement over-
activation is thought to be an important driver of patho-
genesis in early AMD.39
The identiﬁed putative splice-altering and nonsense var-
iants are likely to result in haploinsufﬁciency of both FH
and FHL-1. By contrast, the c.1243del mutation in exon 9 of
CFH is predicted to have differing effects on the 2 isoforms.
In FH (NM_000186), this frameshift is predicted to undergo
nonsense-mediated decay (NMD) whereas in FHL-1
(NM_001014975), this same single base pair deletion is
predicted to result in a frameshift within the penultimate
exon that likely is to escape NMD, creating a stop codon 47
amino acid downstream (p.(Ala415ProfsTer47)) and
resulting in an extension of the normal 449-amino acid
product by 13 amino acids, as well as loss of its unique 4-
amino acid C-terminal tail, which is known to have a role
in the proteins binding to proinﬂammatory monomeric
C-reactive protein.40 Predicting the impact of missense
variants on protein function is challenging, particularly
for the CFH gene.33 Both of the missense variants,
p.(Cys431Ser) and p.(Arg127His), as well as the
p.(Ala415ProfsTer47) frameshift variant, were investigated
in vitro. By expressing these recombinant mutant FHL-1
proteins, we have demonstrated that none of the 3 allowed
the production of a secreted FHL-1 product. We suggest that
all 3 variants also may result in loss of protein function. The
CFH p.(Cys431Ser) variant replaces the highly conserved,
third cysteine residue of the seventh CCP domain. One of
the deﬁning characteristics of a CCP domain is the presence
of 2 disulphide bonds with the cysteineecysteine pattern of
C1eC3 and C2eC4; therefore, this amino acid substitution
likely disrupts the structure and function of CCP domain 7lar drusen with rare CFH variants. A, B, Patient A:II.3, 51 years of age,
, Patient A:II.1, 49 years of age, with drusen extending outside the macular
y at the macula and in the nasal retina in both eyes. G,H, Patient B:I.1, 61
, J, Patient C:I.2, 64 years of age, showing loss of central signal consistent
I.7, 26 years of age, showing geographic atrophy and large colloidal macular
centrally resulting from geographic atrophy with a surrounding ring of
years of age, showing sparse temporal drusen. Q, R, Patient G:III.7, 66 years
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Figure 5. Protein schematic of factor H (FH) and factor H like-1 (FHL-1) showing protein domains and corresponding amino acid positions with locations
of mutations identiﬁed in our early-onset macular drusen cohort. Factor H contains 20 complement control protein (CCP) domains (top), whereas FHL-1
encodes 7 CCP domains (bottom), identical to FH CPP domains 1 through 7. Regions associated with C3b binding are indicated by adjacent red bars,
cofactor activity is indicated by the green bar, heparin binding sites are indicated by blue bars, and the sialic acid binding site is indicated by the purple bar.
The locations of mutations identiﬁed by this study are indicated by dashed grey lines. The parenthetical letter after the mutation nomenclature indicates the
study identiﬁcation of the family in which the mutation was identiﬁed.
Ophthalmology Volume 126, Number 10, October 2019and results in a free cysteine that may interact covalently
with surrounding residues. Functional characterization of a
different amino acid substitution at the same position of theFigure 6. Expression of wild-type and mutant factor H like-1 (FHL-1) in
transfected HEK293 cells. HEK293 cells were transfected stably with His-
tagged wild-type pcDNA3.1-FHL-1 (FHL-1Y402) or 1 of 3 mutant constructs
(FHL-1C431S, FHL-1R127H, or FHL-1A415f/s), as indicated at the top of the gel
image, to assess the effect of the identiﬁed variants on protein expression and
secretion over 144 hours. Recombinant proteins puriﬁed from culture media
(secreted) and cell lysates (intracellular) were subjected to sodium dodecyl
sulfateepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
nitrocellulose membrane. The ﬁgure shows Western blot results from analysis
of experimental samples for OX23. Presence of a band indicates presence of
recombinant FHL-1. Cells transfected with mutants did not secrete a detect-
able FHL-1 product (approximately 51 kDa) in comparison with wild-type
FHL-1. Mock (no DNA) transfected cells did not produce an FHL-1 prod-
uct, as expected. Analysis of cell lysates found no accumulation of mutant
recombinant proteins intracellularly, but wild-type recombinant FHL-1 was
found to be present. SOD2 (approximately 26 kDa) indicates equal sample
loading of cell lysates. OD ¼ right eye; OS ¼ left eye.
1418peptide, p.(Cys431Tyr), showed that it decreased stability of
the recombinant FH.41 Moreover, mass spectrometry
analysis of plasma from the affected patient found that the
protein product of the mutated allele was not present,
suggesting that the change prevents secretion, the mutated
protein is degraded rapidly, or both.41 The CFH
p.(Arg127His) substitution alters CCP domain 2 in a
region of FH and FHL-1 previously shown to be impor-
tant for C3b binding and cofactor activity.35 In vivo
investigations have shown that p.(Arg127His) results in
retention of mutant full-length FH in the endoplasmic re-
ticulum of cultured patient ﬁbroblasts.35 Review of 29 CFH
mutations previously reported as the underlying cause of
EOMD (basal laminar drusen, cuticular drusen, and early-
onset AMD) found that 75.8% impact FHL-1 as well as
FH. This ﬁgure increases to 80.5% on inclusion of the
variants reported by this study. Importantly, all 12 reported
nonsense, splice-altering, and frameshift variants (5 by this
study, 7 reported previously in the literature) fall within
CCP domains 1 through 7. Furthermore, all missense sub-
stitutions (n ¼ 10) affecting CCP domains 1 through 7 that
have been evaluated in vitro have been found to prevent
secretion or to result in loss of protein function. Conse-
quently, at least 81% of reported EOMD variants result in
loss of protein function, strongly supporting the hypothesis
that haploinsufﬁciency of FHL-1 is one important mecha-
nism underpinning the development of drusen in early
adulthood. The contribution of AMD-related loci to EOMD,
if any, remains elusive, but is an important area for future
research. Moreover, identiﬁcation of higher numbers of
affected individuals or families likely would be required to
associate demographics such as age at onset and severity
with AMD risk alleles in this subgroup of patients.
Strict control of innate immunity at BrM is critical for
maintaining normal homeostasis and health of the retina. It
Taylor et al  CFH Mutations Causing Macular Drusenis becoming increasingly apparent that one of the main
pathologic characteristics of AMD is inﬂammation of the
central retina and consequential particulate accumulation
(drusen development), cellular damage, and subsequent loss
of vision as a result of complement dysregulation.42 Factor
H, and almost certainly FHL-1, are the only components of
the complement system known to downregulate alternative
pathway activation on host extracellular matrix and
self-surfaces via interaction with binding partners and
cofactors.12,39 There is increasing evidence that the eye
synthesizes complement pathway components locally,5,43,44
and the importance of functional FHL-1 at the retina is
becoming ever more apparent.26,27,40
It is known that FHL-1 is the only isoform that can diffuse
passively across BrM; FH cannot because of its large size.26
Factor H-like 1 is immobilized in BrM and the ECM of the
choriocapillaris by interaction with heparan sulfate via its
glycosaminoglycan-binding site in CCP domain 7. In this
way, FHL-1 functions to protect the ECM from complement
activation.26 The Y402H polymorphism has been shown to
affect the function of FHL-1; the 402H variant reduces FHL-
1 binding to heparan sulphate.26 According to the GnomAD
database, 44.08% of individuals from all populations (42.6%
in the European [non-Finnish] population) are heterozygous
for the 402H allele, whereas 32.54% of all populations (38.4%
of the European [non-Finnish] population) are homozygous.
Individuals heterozygous for the 402H variant are at a 2-fold
increased risk of AMD, whereas those who are homozygous
have a more than 5-fold increased risk.4 Studies have shown
that although the AMD-associated Y402H allele does not
alter FH protein conformation, nor does it alter FH levels in
blood. It does result in decreased ability of FHL-1 to bind
heparan sulfate26,45,46; any changes to FH binding to glycos-
aminoglycans seems minimal because of this larger protein’s
second glycosaminoglycan-binding site. Furthermore, recent
work has shown that the Y402H polymorphism has a more
pronounced effect on FHL-1 binding of pentraxin 3dan
inﬂammation-associated protein that binds FH at CCP domain
7 and CCP domains 19 and 20 and increases interaction of FH
with apoptotic cells for iC3b opsonizationdthan it does on FH
binding of pentraxin 3, most likely because it affects the only
pentraxin 3 binding site within FHL-1.40 Taken together, this
evidence suggests that loss of FHL-1 expression or function
has a detrimental impact on regulation of the complement
system in the retina.
Previous publications that have identiﬁed rare, highly
penetrant CFH mutations in association with EOMD have
focused on the location of mutations within the FH protein
with respect to known functions of domains.23,37 However,
it is now recognized that FHL-1 is the predominant regulator
of the complement pathway within BrM and the inter-
capillary septa.26 Factor H and FHL-1 both negatively
regulate the alternative complement pathway by competing
for binding to C3b with factor B to govern the removal of
immune complexes and pathogens and to modulate adaptive
immunity. They also serve as cofactors for factor I cleavage
of C3b into its hemolytically inactive state, iC3b. We sug-
gest that pathogenic variations in FHL-1 resulting in loss or
impairment of function are an important cause of EOMD in
the vast majority of patients.There exists a well-recognized genotypeephenotype
correlation with respect to CFH variants and disease, with
variants affecting CCP domains 1 through 4 and CCP do-
mains 6 through 8 mainly causing eye disease, whereas
those affecting CCP domains 19 and 20 causing kidney
disease.17 This is supported by research that has shown the
glycosaminoglycan-binding site in CCP domain 7 demon-
strates selectivity toward heparan sulfates in BrM and the
choriocapillaris, whereas the region of CCP domains 19 and
20 preferentially binds heparan sulfates in the glomerular
basement membrane of the kidneys.12,47 However, a degree
of allelic overlap exists that cannot be explained by our
current understanding of the function of FH and FHL-1,
representing an important area for future research.
In conclusion, rare, deleterious mutations in CFH resulting
in haploinsufﬁciency of FH and FHL-1 are an important and
underrecognized cause of dominant EOMD. Identiﬁcation of
CFH variants underlying EOMD has important consequences
for clinical care, allowing genetic testing of other family
members and counseling where appropriate; the identiﬁcation
of the underlying molecular cause can allow the provision of
more accurate prognostic information, particularly where var-
iants are known to increase the risk of progressing to a severe
phenotype resulting in signiﬁcant visual loss.10,48 Furthermore,
with complement-modulating therapeutics beingdeveloped for
AMD, such genetic analyses may identify subsets of patients
who may beneﬁt from these new treatments. The impact of
variants on the expression or function of FHL-1, or both, have
not been considered previously for EOMD, and we propose
that this truncated formofFHplays a crucial role inEOMDand
potentially AMD. Identiﬁcation of further mutations causing
the rare, genetically heterogeneousEOMDphenotypewill lead
to a better understanding of disease pathogenesis.References
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